GoodRx Expands Employer-Sponsored Access to Zepbound KwikPen
GoodRx to Expand Employer-Sponsored Access to Zepbound® KwikPen® GoodRx the leading platform for prescription savings in the U.S., today announced employer-sponsored access to Zepbound® (tirzepatide) KwikPen® (for single-patient-use) through GoodRx Employer Direct. As one of Lilly’s Employer Connect independent program administrators, GoodRx…
MindWalk Introduces B Cell Llama™, Expanding Nanobody Discovery for Cell and Bispecific Therapies
MindWalk Announces B Cell Llama™, a Nanobody Discovery Platform Designed for the Bispecific and Cell Therapy Era MindWalk Holdings Corp. a bio-native AI company, today announced B Cell Llama™, a platform for the discovery of VHH nanobodies: the single-domain antibody fragments…
Lone Star Funds to Acquire Lonza Group AG’s Capsules and Health Ingredients Business
Lone Star Funds Signs Agreement to Buy Lonza’s Capsules and Health Ingredients Division Lone Star Funds has announced a major strategic investment through an agreement to acquire the Capsules & Health Ingredients (CHI) business from Lonza Group AG, marking a…
Savara Reports Regulatory Update for MOLBREEVI in Autoimmune PAP Treatment Development
Savara Provides Regulatory Update on MOLBREEVI Development Program for Autoimmune Pulmonary Alveolar Proteinosis Savara clinical-stage biopharmaceutical company focused on developing treatments for rare respiratory diseases, has announced a significant regulatory update regarding its investigational therapy MOLBREEVI, which is being developed…
FDA Approves Sotyktu for Adults with Active Psoriatic Arthritis
FDA Greenlights Sotyktu to Treat Active Psoriatic Arthritis in Adults The U.S. Food and Drug Administration (FDA) has approved Sotyktu (deucravacitinib), developed by Bristol Myers Squibb, for the treatment of adults living with Psoriatic Arthritis (PsA). This approval introduces a…
Liberate Bio Secures Myeloid-Optimized CAR Design Licenses to Advance In Vivo CAR-M Programs
Liberate Bio Secures Myeloid-Optimized CAR Design Licenses to Advance In Vivo CAR-M Programs Liberate Bio, Inc., a biotechnology company developing genetic medicines that deliver RNA therapies directly to immune cells, announces that it has secured exclusive and non-exclusive licenses to…
Parabilis Medicines Reports Early Clinical Evidence Showing Zolucatetide Reduces Polyp Burden in a Patient with Familial Adenomatous Polyposis
Parabilis Medicines Reports Early Clinical Evidence that Zolucatetide Reduces Polyp Burden in a Patient with Familial Adenomatous Polyposis Parabilis Medicines, a clinical-stage biopharmaceutical company committed to creating extraordinary medicines for people living with cancer using its Helicon™ peptide platform to…
Response Pharmaceuticals Reports Positive 36-Week Phase 2 Data Supporting RDX-002 for Long-Term Post-GLP-1 Weight Management
Response Pharmaceuticals Reports Positive 36-Week Phase 2 Data Supporting RDX-002 as a Long-Term Option in Post-GLP-1 Receptor Agonist Weight Management Response Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing therapies for weight management and metabolic health, reinforces its position as a…
Mirum Pharmaceuticals Provides AZURE Clinical Program Update for Brelovitug in Chronic Hepatitis Delta Virus
Mirum Pharmaceuticals Provides AZURE Clinical Program Update for brelovitug in Chronic Hepatitis Delta Virus Mirum Pharmaceuticals, Inc. a leading rare disease company, today announced completion of enrollment in the Phase 3 AZURE-1 study and completion of screening in the Phase…
DiaMedica Therapeutics Receives Health Canada Clearance to Launch Phase 2 Study of DM199 for Preeclampsia
DiaMedica Therapeutics Receives Health Canada Clearance to Initiate Phase 2 Study of DM199 in Preeclampsia DiaMedica Therapeutics Inc. a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke (AIS), today announced that…
Silence Therapeutics Highlights Recent Business Achievements and Reports Fourth Quarter and Full-Year 2025 Financial Results
Silence Therapeutics Highlights Recent Business Achievements and Reports Fourth Quarter and Full Year 2025 Financial Results Silence Therapeutics plc, a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today reported financial results for the fourth quarter and full…
Affinia Therapeutics’ AFTX-201 Earns FDA Fast Track Designation for BAG3-Associated Dilated Cardiomyopathy
Affinia Therapeutics Granted FDA Fast Track Designation for AFTX-201 as a Treatment for People Living with BAG3-Associated Dilated Cardiomyopathy (DCM) Affinia Therapeutics an innovative gene therapy company with a pipeline of first-in-class and/or best-in-class adeno-associated virus (AAV) gene therapies initially…